Swiss Pharma Industry Urges Tariff Reduction to Protect Exports
Switzerland's pharmaceutical industry, a key driver of the country's exports, is calling for continued dialogue to reduce or eliminate tariffs on drugs. Interpharma, the association representing Swiss pharmaceutical companies, warns that customs barriers are disrupting production and supply chains, and could permanently harm close economic ties between Switzerland and the US.
In 2024, the Swiss pharmaceutical industry exported medicines worth over CHF100 billion, making it the nation's most important export sector. Interpharma urges Swiss politicians to send clear signals to maintain international competitiveness. This includes suspending new regulatory projects and modernizing the pricing mechanism for innovative therapies.
The association hopes that bilateral talks can continue to reduce or exempt tariffs on drugs. It warns that US tariffs on medicines threaten global drug supply chains. However, there is no specific organization mentioned that has announced this threat and has specific demands for Swiss politicians.
Interpharma emphasizes the need for a comprehensive life sciences strategy in the medium term, to be developed jointly by the federal administration, politics, and industry. This strategy aims to ensure the competitiveness and sustainability of the Swiss pharmaceutical industry in the face of global challenges.
